DelveInsight’s Cushing’s Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Cushing’s Syndrome Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Cushing’s syndrome Market report covers emerging drugs, current treatment practices, market share of the individual therapies, and the current forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.
Cushing’s Syndrome: An Overview
Cushing’s Syndrome (CS) is a disorder that occurs when body makes too much of the hormone cortisol over a long period of time. Cortisol is sometimes called the “stress hormone” because it helps body respond to stress.
Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/cushings-syndrome-market
Some of the key facts of the Cushing’s Syndrome market report
- According to the Orphanet, the prevalence of endogenous Cushing’s Syndrome (CS) is 1/26,000 and, in the EU, it has an annual prevalence of 1/1,400,000-1/400,000, with a peak prevalence at 25-40 years of age.
- As per the National Organization for Rare Disorders, it is reported that the incidence of endogenous Cushing syndrome is approximately 13 per million people annually.
- According to the “National Organization for Rare Disorders”, Cushing syndrome caused by either an adrenal or pituitary tumor affects females five times more frequently than males. Symptoms commonly begin between 25 to 40 years of age. Men are affected 3 times more than women by ectopic ACTH production that is caused by lung cancer, which occurs later in life.
- According to the American Association of Neurological Surgeons, Cushing’s Syndrome is more common among females as compared to males.
Cushing’s Syndrome Market
The Cushing’s Syndrome market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of the Cushing’s Syndrome Market in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Cushing’s Syndrome Market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Cushing’s Syndrome Market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Cushing’s Syndrome Market Insights
The modern view of the medical treatment of Cushing’s Syndrome (CS) is based on the concept of the tailoring of treatment, which should be chosen in order to be adapted to the single patient on the basis of the patient’s features (gender and desire of conception), disease characteristics (disease severity and duration, and presence and comorbidites, and concomitant medications), and tumor features (microadenoma or macroadenoma, invisible tumor, or aggressive tumor), besides the consideration of the ratio between costs and benefits of the specific treatment.
Cushing’s Syndrome Treatment Market
Treatment of Cushing’s Syndrome (CS) depends on the cause and may include surgery, radiation, chemotherapy, or cortisol-reducing medicines. If the cause is long-term use of glucocorticoids to treat another disorder, the doctor will gradually reduce the dosage to the lowest dose that will control that disorder. Sometimes disorders that doctors treat with glucocorticoids can be treated with a non-glucocorticoid medicine instead. The first-line treatment for CD is presently pituitary surgery by the transsphenoidal approach, aiming at removal of the pituitary tumor. However, aside from the possibility of hypopituitarism, nearly one third of patients will experience an immediate failure or subsequent relapse during the 10 years after surgery. Therefore, a significant percentage of patients will require a second-line treatment approach. Second-line treatment may be represented by a repeat surgery, which is however associated with a lower chance of success and higher chance of hypopituitarism compared with the initial surgery, or more radical treatments such as pituitary radiotherapy and bilateral adrenalectomy.
Download Free Sample Report @ https://www.delveinsight.com/sample-request/cushings-syndrome-market
Cushing’s Syndrome Epidemiology
The epidemiology section covers insights into the historical and current Cushing’s Syndrome Market patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Cushing’s Syndrome Drugs & Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cushing’s Syndrome Market or expected to get launched in the market during the study period. The analysis covers Cushing’s Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Cushing’s Syndrome Market Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies. Unmet needs in the Cushing’s Syndrome include therapies that are oral, anthracycline sparing and deliverable in resource-limited settings. Another major unmet need is the relapse and refractory cases in the patients given treatment with Doxil.
Cushing’s Syndrome Market Dynamics
The dynamics of Cushing’s Syndrome market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period of 2021–2030.
Cushing’s Syndrome Market Companies
- Recordati
- Corcept Therapeutics
- Strongbridge Biopharma
- AstraZeneca, and several others
Cushing’s Syndrome Market Drugs
- AZD4017
- Recorlev
- Relacorilant
- Isturisa
- Signifor, and several others
Read Full Research Report @ https://www.delveinsight.com/sample-request/cushings-syndrome-market
Table of content
- Key Insights
- Executive Summary
- Competitive Intelligence Analysis
- Market Overview at a Glance
- Disease Background and Overview
- Patient Journey
- Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Unmet Needs
- Key Endpoints of Cushing’s Syndrome Market Treatment
- Marketed Products
- Emerging Therapies
- Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview
- KOL Views
- Market Drivers
- Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/